Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Finished Goods: 2020-2021

Historic Finished Goods for UroGen Pharma (URGN) over the last 1 years, with Mar 2021 value amounting to $888,000.

  • UroGen Pharma's Finished Goods was N/A to $888,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $888,000, marking a year-over-year change of. This contributed to the annual value of $913,000 for FY2020, which is N/A change from last year.
  • As of Q1 2021, UroGen Pharma's Finished Goods stood at $888,000, which was down 2.74% from $913,000 recorded in Q4 2020.
  • Over the past 5 years, UroGen Pharma's Finished Goods peaked at $913,000 during Q4 2020, and registered a low of $232,000 during Q2 2020.
  • Moreover, its 2-year median value for Finished Goods was $653,500 (2020), whereas its average is $613,000.